Theoretical pharmacokinetic advantages and methodological flaws: glargine is not superior to NPH insulin in children with type 1 diabetes mellitus

Arq Bras Endocrinol Metabol. 2010 Feb;54(1):81-3. doi: 10.1590/s0004-27302010000100014.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Comment

MeSH terms

  • Child
  • Child, Preschool
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Glycated Hemoglobin / analysis
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / pharmacokinetics
  • Infant
  • Infant, Newborn
  • Insulin / adverse effects
  • Insulin / analogs & derivatives*
  • Insulin / pharmacokinetics
  • Insulin Glargine
  • Insulin, Isophane / adverse effects*
  • Insulin, Isophane / pharmacokinetics
  • Insulin, Long-Acting
  • Research Design / standards*

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Insulin, Long-Acting
  • Insulin Glargine
  • Insulin, Isophane